Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05583227




Registration number
NCT05583227
Ethics application status
Date submitted
13/10/2022
Date registered
17/10/2022
Date last updated
4/06/2024

Titles & IDs
Public title
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Scientific title
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
Secondary ID [1] 0 0
2022-001294-31
Secondary ID [2] 0 0
D5244C00001
Universal Trial Number (UTN)
Trial acronym
CROSSING
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Eosinophilic Esophagitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Inflammatory and Immune System 0 0 0 0
Allergies

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Tezepelumab
Other interventions - Tezepelumab
Other interventions - Placebo

Experimental: Tezepelumab Low Dose - Tezepelumab subcutaneous injections, in accessorised pre-filled syringes

Experimental: Tezepelumab High Dose - Tezepelumab subcutaneous injections, in accessorised pre-filled syringes

Placebo Comparator: Placebo - Placebo subcutaneous injections, in accessorised pre-filled syringes


Other interventions: Tezepelumab
Tezepelumab subcutaneous injection

Other interventions: Tezepelumab
Tezepelumab subcutaneous injection

Other interventions: Placebo
Placebo subcutaneous injection
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Histologic response of peak esophageal eosinophil per HPF count of = 6 across all available esophageal levels
Timepoint [1] 0 0
Week 24
Primary outcome [2] 0 0
Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score
Timepoint [2] 0 0
Week 24
Secondary outcome [1] 0 0
Change from baseline in EoE EREFS (Endoscopic reference score )
Timepoint [1] 0 0
Week 24, Week 52
Secondary outcome [2] 0 0
Change from baseline in EoE-HSS (Histologic scoring system) grade score
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Change from baseline in EoE-HSS (Histologic scoring system) stage score
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
Histologic response of peak esophageal eosinophil per HPF count of = 6 across all available esophageal levels
Timepoint [4] 0 0
Week 52
Secondary outcome [5] 0 0
Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score
Timepoint [5] 0 0
Week 52
Secondary outcome [6] 0 0
Response of achieving clinico-histological remission
Timepoint [6] 0 0
Week 24, Week 52

Eligibility
Key inclusion criteria
1. Participant must be 12 to 80 years of age inclusive, at the time of signing the
informed consent/assent.

2. Weight = 40 kg at Visit 1

3. Established diagnosis of EoE with a previous EGD and esophageal biopsy confirming a
diagnosis of EoE.

4. Participants who have symptomatic EoE as defined by a history of on average at least 2
episodes of dysphagia (any severity of food going down slowly or being stuck in the
throat) per week in the 4 weeks prior to Visit 1.

5. Must remain on a stabilized diet for at least 8 weeks prior to Visit 1 and during the
course of the study (stable diet is defined as no initiation of single or multiple
elimination diets or reintroduction of previously eliminated food groups).

6. May be on any background PPI and/or STC, during the course of the study, as long as
background medications have been stable for at least 8 weeks prior to the
screening/run-in period (Visit 1) and there is agreement not to change background
medication or dosage unless medically indicated, during the screening/run-in and
treatment period.

7. Participants currently on leukotriene inhibitors and/or steroid treatments for asthma
or allergies that are inhaled or administered intranasally, must report a stable dose
for at least 4 weeks prior to the screening/run-in period (Visit 1).

8. If a medication for EoE (for example PPI and/or STC) is discontinued prior to the
screening/run-in, there should be a washout period of at least 8 weeks prior to Visit
1. Discontinuation of any marketed biologic (monoclonal or polyclonal antibody) should
have a washout period of 4 months or 5 half-lives prior to Visit 1, whichever is
longer.

9. Participants should have previously documented standard of care treatment, which could
include PPI and/or STC and/or diet.
Minimum age
12 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Other gastrointestinal disorders such as active Helicobacter pylori infection, history
of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory
bowel disease, celiac disease, eosinophilic enteritis, colitis, diverticulitis,
irritable bowel syndrome, or other clinically significant gastrointestinal conditions
as per Investigator discretion.

2. Esophageal stricture that prevents the easy passage of a standard endoscope or any
critical esophageal stricture that requires dilation at screening.

3. Use of a feeding tube, or having a pattern of not eating solid food >3 days of week.
Solid food is defined as food that requires chewing before swallowing.

4. Hypereosinophilic syndrome

5. EGPA vasculitis

6. Esophageal dilation performed within 8 weeks prior to screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
8/01/2027
Actual
Sample size
Target
360
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Elizabeth Vale
Recruitment hospital [2] 0 0
Research Site - Kogarah
Recruitment hospital [3] 0 0
Research Site - Mitcham
Recruitment hospital [4] 0 0
Research Site - South Brisbane
Recruitment hospital [5] 0 0
Research Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
3132 - Mitcham
Recruitment postcode(s) [4] 0 0
QL 4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Austria
State/province [24] 0 0
Graz
Country [25] 0 0
Austria
State/province [25] 0 0
Wels-Grieskirchen
Country [26] 0 0
Austria
State/province [26] 0 0
Wien
Country [27] 0 0
Belgium
State/province [27] 0 0
Brugge
Country [28] 0 0
Belgium
State/province [28] 0 0
Edegem
Country [29] 0 0
Belgium
State/province [29] 0 0
Gent
Country [30] 0 0
Belgium
State/province [30] 0 0
Leuven
Country [31] 0 0
Brazil
State/province [31] 0 0
Botucatu
Country [32] 0 0
Brazil
State/province [32] 0 0
Brasilia
Country [33] 0 0
Brazil
State/province [33] 0 0
Caxias do Sul
Country [34] 0 0
Brazil
State/province [34] 0 0
Curitiba
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre
Country [36] 0 0
Brazil
State/province [36] 0 0
Sao Paulo
Country [37] 0 0
Brazil
State/province [37] 0 0
São José do Rio Preto
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
China
State/province [40] 0 0
Beijing
Country [41] 0 0
China
State/province [41] 0 0
Changsha
Country [42] 0 0
China
State/province [42] 0 0
Guangzhou
Country [43] 0 0
China
State/province [43] 0 0
Hangzhou
Country [44] 0 0
China
State/province [44] 0 0
Nanjing
Country [45] 0 0
China
State/province [45] 0 0
Shanghai
Country [46] 0 0
China
State/province [46] 0 0
Shenyang
Country [47] 0 0
China
State/province [47] 0 0
Tianjin
Country [48] 0 0
China
State/province [48] 0 0
Wuhan
Country [49] 0 0
China
State/province [49] 0 0
Zhengzhou
Country [50] 0 0
Czechia
State/province [50] 0 0
Brno
Country [51] 0 0
Czechia
State/province [51] 0 0
Hradec Kralove
Country [52] 0 0
Czechia
State/province [52] 0 0
Praha
Country [53] 0 0
Denmark
State/province [53] 0 0
Aalborg
Country [54] 0 0
Denmark
State/province [54] 0 0
Køge
Country [55] 0 0
Denmark
State/province [55] 0 0
Odense
Country [56] 0 0
Finland
State/province [56] 0 0
Helsinki
Country [57] 0 0
Finland
State/province [57] 0 0
Hämeenlinna
Country [58] 0 0
Finland
State/province [58] 0 0
Kuopio
Country [59] 0 0
Finland
State/province [59] 0 0
Turku
Country [60] 0 0
Germany
State/province [60] 0 0
Frankfurt
Country [61] 0 0
Germany
State/province [61] 0 0
Landsberg
Country [62] 0 0
Germany
State/province [62] 0 0
München
Country [63] 0 0
Greece
State/province [63] 0 0
Athens
Country [64] 0 0
Greece
State/province [64] 0 0
Thessaloniki
Country [65] 0 0
Israel
State/province [65] 0 0
Haifa
Country [66] 0 0
Israel
State/province [66] 0 0
Holon
Country [67] 0 0
Israel
State/province [67] 0 0
Jerusalem
Country [68] 0 0
Israel
State/province [68] 0 0
Petah Tikva
Country [69] 0 0
Israel
State/province [69] 0 0
Tel Aviv
Country [70] 0 0
Israel
State/province [70] 0 0
Tel Hashomer
Country [71] 0 0
Italy
State/province [71] 0 0
Bologna
Country [72] 0 0
Italy
State/province [72] 0 0
Milano
Country [73] 0 0
Italy
State/province [73] 0 0
Napoli
Country [74] 0 0
Italy
State/province [74] 0 0
Padova
Country [75] 0 0
Italy
State/province [75] 0 0
Pisa
Country [76] 0 0
Italy
State/province [76] 0 0
Roma
Country [77] 0 0
Italy
State/province [77] 0 0
Rozzano
Country [78] 0 0
Italy
State/province [78] 0 0
Verona
Country [79] 0 0
Japan
State/province [79] 0 0
Akita-shi
Country [80] 0 0
Japan
State/province [80] 0 0
Fukuoka-shi
Country [81] 0 0
Japan
State/province [81] 0 0
Himeji
Country [82] 0 0
Japan
State/province [82] 0 0
Hiroshima-shi
Country [83] 0 0
Japan
State/province [83] 0 0
Isehara-shi
Country [84] 0 0
Japan
State/province [84] 0 0
Kawasaki-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Kitakyushu-shi
Country [86] 0 0
Japan
State/province [86] 0 0
Maebashi-shi
Country [87] 0 0
Japan
State/province [87] 0 0
Minato-ku
Country [88] 0 0
Japan
State/province [88] 0 0
Osaka
Country [89] 0 0
Japan
State/province [89] 0 0
Shinjuku-ku
Country [90] 0 0
Japan
State/province [90] 0 0
Yamagata-shi
Country [91] 0 0
Netherlands
State/province [91] 0 0
Amsterdam
Country [92] 0 0
Netherlands
State/province [92] 0 0
Nijmegen
Country [93] 0 0
Netherlands
State/province [93] 0 0
Rotterdam
Country [94] 0 0
New Zealand
State/province [94] 0 0
Christchurch
Country [95] 0 0
New Zealand
State/province [95] 0 0
Grafton
Country [96] 0 0
New Zealand
State/province [96] 0 0
Hamilton
Country [97] 0 0
New Zealand
State/province [97] 0 0
Newtown
Country [98] 0 0
New Zealand
State/province [98] 0 0
Otahuhu
Country [99] 0 0
Norway
State/province [99] 0 0
Lørenskog
Country [100] 0 0
Norway
State/province [100] 0 0
Oslo
Country [101] 0 0
Norway
State/province [101] 0 0
Tromsø
Country [102] 0 0
Norway
State/province [102] 0 0
Ålesund
Country [103] 0 0
Slovakia
State/province [103] 0 0
Kosice
Country [104] 0 0
Slovakia
State/province [104] 0 0
Martin
Country [105] 0 0
Spain
State/province [105] 0 0
Barcelona
Country [106] 0 0
Spain
State/province [106] 0 0
Bilbao (Vizcaya)
Country [107] 0 0
Spain
State/province [107] 0 0
Madrid
Country [108] 0 0
Spain
State/province [108] 0 0
Pamplona
Country [109] 0 0
Spain
State/province [109] 0 0
Sevilla
Country [110] 0 0
Spain
State/province [110] 0 0
Tomelloso
Country [111] 0 0
Sweden
State/province [111] 0 0
Stockholm
Country [112] 0 0
Sweden
State/province [112] 0 0
Trollhättan
Country [113] 0 0
Sweden
State/province [113] 0 0
Uppsala
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Brighton
Country [115] 0 0
United Kingdom
State/province [115] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Amgen
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the
efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized
pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic
esophagitis (EoE).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05583227
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05583227